Zhong Nanshan, academician of the Chinese Academy of Engineering, said at the theme sharing meeting of the first Zhong Nanshan Youth Science and Technology Innovation Award held in Guangzhou in Guangzhou on January 6th that China is currently the country with the lowest death rate from new coronary pneumonia, with a prevalence rate of 9.4 /100000, the mortality rate is 0.4/100000.

　　Zhong Nanshan introduced that as of January 6, the population in China who had completed the full vaccination of the new crown pneumonia vaccine reached 1.213 billion people, and the vaccine injection rate reached 86%; 331 million people had completed the booster vaccination vaccine, and the booster injection rate reached 23.5%.

　　[Concurrent] Zhong Nanshan, Academician of Chinese Academy of Engineering

　　Theoretically speaking (the purpose of herd immunity in China) has been achieved, but as I said originally, it was originally against wild strains. Now for Delta, and even for Omi Keron, which may have community infections in China, It is entirely possible that it needs to be strengthened (vaccinations), but it should be said that from a lot of our treatments, we do not have (death cases) in Guangzhou. This is related to the original vaccines, and there are no serious deaths. So I think this is achieved (herd immunity) in a certain sense.

　　[Explanation] In response to this round of Xi'an epidemic, Zhong Nanshan analyzed that Xi'an has adopted extremely strict prevention and control measures, and it seems to be effective now.

　　[Concurrent] Zhong Nanshan, Academician of Chinese Academy of Engineering

　　Xi'an now has more than 1,800 cases (confirmed cases), but it has reached its peak, and it has reached an inflection point. At its peak, it was 172 (confirmed cases) a day, and (January 5) there were 63 cases.

　　[Explanation] In addition, Zhong Nanshan said for the newly emerging variant of the new coronavirus strain IHU.

　　[Concurrent] Zhong Nanshan, Academician of Chinese Academy of Engineering

　　It is too early for IHU to become a virus as widely as Delta, and I don’t think it needs to be interpreted too much.

It has more than 40 mutation sites than (Omi Kirundo). Of course, theoretically, its immune escape ability (for vaccines) and its resistance to some antibodies may be stronger.

But do you want to make a vaccine right away? I don't think it is time. It needs an observation process. What to observe? The key is whether it will become a mainstream virus.

　　Reporting by reporter Wei Jiefu from Guangdong

Editor in charge: [Lu Yan]